Thomas Dietz

Thomas John Dietz currently works at Waypoint Holdings LLC, as Chairman & Chief Executive Officer from 2010, Galleon Pharmaceuticals, Inc., as Chairman, AgBiome INC, as Director from 2014, Glialogix, Inc., as Director, Cypherpunk Technologies, Inc., as Lead Independent Director from 2016, Nutcracker Therapeutics, Inc., as Director from 2023, California Pacific Medical Center, as Trustee, Codfish Investments LLC, as Managing Member from 2012, and Codpiece Properties LLC, as Managing Member from 2012.
Dr. Dietz also formerly worked at Pacific Growth Equities, Inc., as Chief Executive Officer & Director from 2004 to 2009, Eiger BioPharmaceuticals, Inc., as Independent Non-Executive Chairman from 2016 to 2024, Virobay, Inc., as Independent Director, Eiger BioPharmaceuticals, Inc., as Independent Director from 2015 to 2016, Transcept Pharma, Inc., as Independent Director from 2013 to 2014, Paratek Pharmaceuticals, Inc., as Independent Director from 2014 to 2023, Wedbush Securities, Inc., as Head-Investment Banking from 2009 to 2010, The University of California, San Francisco, as Member-Research Faculty, Sutter Health, as Trustee-West Bay Region, and VA Medical Center (District of Columbia), as Research Faculty Member.
Dr. Dietz received his doctorate degree in 1990 from Washington University in St. Louis and undergraduate degree from State University of New York at Albany.